Clearpoint Neuro Inc

CLPT remains in a Stage 2 advancing corrective reset with clear higher highs and higher lows. Price is currently extended above rising short-term EMAs and in extreme overbought territory, and the late-June bearish exhaustion candle signals waning upside momentum and a likely pullback. Under a Speculative strategy, high asymmetry and defined structure are required, so patience is advised. A pullback toward the 9/21 EMA zone offers a more favorable entry for continuation participation.

• ↑Q1 2026 revenue $12.1M, 43% YoY growth via organic sales and acquisitions
• ↑Gross margin rose to 64% from 60% YoY
• ↓Severely negative margins and weak profitability metrics persist